Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

US12097204B2 · kind B2 · utility

Assignees

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN
• LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. · CN
• CENTAURUS BIOPHARMA CO., LTD. · CN

Inventors

• Yuanyuan Sun · Beijing, CN
• Shan Zhou · Lianyungang, CN
• Lei Liu · Thousand Oaks, US
• Ping Dong · 安丰镇, CN
• Jing Gao · 安丰镇, CN
• Laicun Li · Lianyungang, CN
• Zhilin Chen · Lianyungang, CN
• Yi Xu · Lianyungang, CN
• Shang Wang · Lianyungang, CN

Key dates

• Filing date: Sep 3, 2019
• Grant date: Sep 24, 2024
• Expiry date: Oct 30, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/2095
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A solid pharmaceutical composition containing a 1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof and a preparation method therefor. In particular, involved are a solid pharmaceutical composition containing 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazine-2-amine or a pharmaceutically acceptable salt thereof and a preparation method therefor. The solid pharmaceutical composition has a good stability, a fast dissolution rate and a high bioavailability, and is suitable for clinical production and use.